Stocky turns companies like Bicara Therapeutics Inc. Common Stock into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Bicara Therapeutics Inc. Common Stock's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Board changes affect company leadership and governance, which impacts how the company is managed and directed.
Shareholders voted on company leadership; 85% participation shows investor engagement in governance decisions.
Clinical trial results determine whether the company's drug candidate can succeed and generate future revenue.
Quarterly earnings show company progress and cash burn, critical for evaluating investment health.
Quarterly earnings show company progress and cash burn, critical for evaluating investment health.
Annual earnings reveal company performance, burn rate, and runway for continued operations.
Annual earnings reveal company performance, burn rate, and runway for continued operations.
Stocky reads Bicara Therapeutics Inc. Common Stock's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Bicara Therapeutics Inc. Common Stock's most recent tracked filing was a 8-K on 28 Jul 2026: Kiran Mazumdar-Shaw resigns; two directors appointed.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.